Journal
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 43, Issue 1, Pages 95-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2016.09.009
Keywords
Progressive multifocal leukoencephalopathy; Biologic therapy; Synthetic immunosuppressive therapy; Autoimmune rheumatic diseases; Systemic lupus erythematosus; Rituximab
Categories
Ask authors/readers for more resources
Progressive multifocal leukoencephalopathy (PML) is a rare, typically fatal, demyelinating central nervous system infection caused by reactivation of the John Cunningham virus that generally occurs in immunosuppressed patients. With an evolving understanding of a greater clinical heterogeneity of PML and significant implications for therapy, PML should be considered in the differential diagnosis of neurologic presentations of rheumatic diseases. Increased awareness of PML among rheumatologists is required, as earlier diagnosis and restoration of immune function may improve the otherwise grim prognosis associated with PML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available